Description: BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Home Page: www.biolinerx.com
Modi’in Technology Park
Hevel Modi'in,
7177871
Israel
Phone:
972 8 642 9100
Officers
| Name | Title |
|---|---|
| Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA | Chief Exec. Officer |
| Ms. Mali Zeevi CPA, CPA | Chief Financial Officer |
| Dr. Ella Sorani | Chief Devel. Officer |
| Mr. John Lacey | Head of Corp. Communications & Investor Relations |
| Advocate Norman Kotler | Internal Enforcement Officer, Gen. Counsel and Corp. Sec. |
| Ms. Liron Shemesh-Darvish M.B.A., Ph.D. | Sr. Director & Head of Preclinical Devel. |
| Ms. Jael Birenberg M.Sc. | Sr. Director & Head of RA, QA and PhV |
| Ms. Tsipi Keren-Lehrer B.Sc., L.L.B. | Head of BD & Strategic Advisor |
| Ms. Holly W. May M.B.A. | Pres of BioLineRx USA |
| Mr. Raziel Fried | Treasurer & Budgetary Control Director |
Exchange: TA
Country: IL
Currency: Israeli Agora (ILA)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7684 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2011-07-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 38 |